WO2009022100A1 - Composition contenant des particules de composé métallique - Google Patents
Composition contenant des particules de composé métallique Download PDFInfo
- Publication number
- WO2009022100A1 WO2009022100A1 PCT/GB2008/002660 GB2008002660W WO2009022100A1 WO 2009022100 A1 WO2009022100 A1 WO 2009022100A1 GB 2008002660 W GB2008002660 W GB 2008002660W WO 2009022100 A1 WO2009022100 A1 WO 2009022100A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- particles
- antiviral
- composition
- article
- tungsten
- Prior art date
Links
- 239000002245 particle Substances 0.000 title claims abstract description 81
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- 150000002736 metal compounds Chemical class 0.000 title description 2
- 230000000840 anti-viral effect Effects 0.000 claims abstract description 28
- 238000000034 method Methods 0.000 claims abstract description 22
- 150000003658 tungsten compounds Chemical class 0.000 claims abstract description 20
- UONOETXJSWQNOL-UHFFFAOYSA-N tungsten carbide Chemical compound [W+]#[C-] UONOETXJSWQNOL-UHFFFAOYSA-N 0.000 claims abstract description 19
- 150000001450 anions Chemical class 0.000 claims abstract description 12
- 229910052755 nonmetal Inorganic materials 0.000 claims abstract description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229910052752 metalloid Inorganic materials 0.000 claims abstract description 8
- 150000002738 metalloids Chemical class 0.000 claims abstract description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 7
- 229910052710 silicon Inorganic materials 0.000 claims abstract description 6
- 239000010703 silicon Substances 0.000 claims abstract description 6
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims abstract description 4
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229910019142 PO4 Inorganic materials 0.000 claims abstract description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 4
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 4
- 239000001301 oxygen Substances 0.000 claims abstract description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims abstract description 4
- 239000010452 phosphate Substances 0.000 claims abstract description 4
- 229910052714 tellurium Inorganic materials 0.000 claims abstract description 4
- PORWMNRCUJJQNO-UHFFFAOYSA-N tellurium atom Chemical compound [Te] PORWMNRCUJJQNO-UHFFFAOYSA-N 0.000 claims abstract description 4
- 241000700605 Viruses Species 0.000 claims description 50
- 229910052721 tungsten Inorganic materials 0.000 claims description 15
- 230000009467 reduction Effects 0.000 claims description 14
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 claims description 14
- 239000010937 tungsten Substances 0.000 claims description 14
- 230000005540 biological transmission Effects 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 10
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 7
- 239000003443 antiviral agent Substances 0.000 claims description 5
- 229940121375 antifungal agent Drugs 0.000 claims description 2
- 239000003429 antifungal agent Substances 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 8
- 239000003960 organic solvent Substances 0.000 abstract description 4
- 239000000463 material Substances 0.000 description 9
- 230000003612 virological effect Effects 0.000 description 9
- 238000000576 coating method Methods 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 7
- 229910052751 metal Inorganic materials 0.000 description 7
- 239000002184 metal Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 6
- -1 for example Substances 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 230000014599 transmission of virus Effects 0.000 description 6
- 229920000742 Cotton Polymers 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 4
- 206010064097 avian influenza Diseases 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 239000004744 fabric Substances 0.000 description 4
- 230000035931 haemagglutination Effects 0.000 description 4
- 229920000728 polyester Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000009423 ventilation Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000315672 SARS coronavirus Species 0.000 description 3
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 230000001524 infective effect Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 229910052709 silver Inorganic materials 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 229920002994 synthetic fiber Polymers 0.000 description 3
- 241000271566 Aves Species 0.000 description 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- QPLDLSVMHZLSFG-UHFFFAOYSA-N Copper oxide Chemical compound [Cu]=O QPLDLSVMHZLSFG-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 208000002979 Influenza in Birds Diseases 0.000 description 2
- 241000714209 Norwalk virus Species 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 241000713311 Simian immunodeficiency virus Species 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 2
- 238000004378 air conditioning Methods 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 239000004411 aluminium Substances 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- KJKGDABVJRFJDD-UHFFFAOYSA-I dihydroxy(dioxo)tungsten;stiboric acid Chemical compound O[Sb](O)(O)=O.O[W](O)(=O)=O KJKGDABVJRFJDD-UHFFFAOYSA-I 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- SZVJSHCCFOBDDC-UHFFFAOYSA-N ferrosoferric oxide Chemical compound O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 2
- 239000011152 fibreglass Substances 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229910052719 titanium Inorganic materials 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 230000003253 viricidal effect Effects 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 244000198134 Agave sisalana Species 0.000 description 1
- 229910017944 Ag—Cu Inorganic materials 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 240000000491 Corchorus aestuans Species 0.000 description 1
- 235000011777 Corchorus aestuans Nutrition 0.000 description 1
- 235000010862 Corchorus capsularis Nutrition 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 229920000271 Kevlar® Polymers 0.000 description 1
- 229920000433 Lyocell Polymers 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 229920001410 Microfiber Polymers 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical group CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 229910007271 Si2O3 Inorganic materials 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 102100021696 Syncytin-1 Human genes 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 229910011208 Ti—N Inorganic materials 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 229910052769 Ytterbium Inorganic materials 0.000 description 1
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000005275 alloying Methods 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 239000002216 antistatic agent Substances 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 239000012237 artificial material Substances 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- IVMYJDGYRUAWML-UHFFFAOYSA-N cobalt(II) oxide Inorganic materials [Co]=O IVMYJDGYRUAWML-UHFFFAOYSA-N 0.000 description 1
- UBEWDCMIDFGDOO-UHFFFAOYSA-N cobalt(II,III) oxide Inorganic materials [O-2].[O-2].[O-2].[O-2].[Co+2].[Co+3].[Co+3] UBEWDCMIDFGDOO-UHFFFAOYSA-N 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- BERDEBHAJNAUOM-UHFFFAOYSA-N copper(I) oxide Inorganic materials [Cu]O[Cu] BERDEBHAJNAUOM-UHFFFAOYSA-N 0.000 description 1
- 229910052593 corundum Inorganic materials 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- KRFJLUBVMFXRPN-UHFFFAOYSA-N cuprous oxide Chemical compound [O-2].[Cu+].[Cu+] KRFJLUBVMFXRPN-UHFFFAOYSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000009189 diving Effects 0.000 description 1
- 239000002019 doping agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- 239000002657 fibrous material Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229910000286 fullers earth Inorganic materials 0.000 description 1
- 229910052733 gallium Inorganic materials 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 239000004761 kevlar Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005551 mechanical alloying Methods 0.000 description 1
- 239000002923 metal particle Substances 0.000 description 1
- 239000003658 microfiber Substances 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 229910003455 mixed metal oxide Inorganic materials 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- GKTNLYAAZKKMTQ-UHFFFAOYSA-N n-[bis(dimethylamino)phosphinimyl]-n-methylmethanamine Chemical compound CN(C)P(=N)(N(C)C)N(C)C GKTNLYAAZKKMTQ-UHFFFAOYSA-N 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- GNRSAWUEBMWBQH-UHFFFAOYSA-N nickel(II) oxide Inorganic materials [Ni]=O GNRSAWUEBMWBQH-UHFFFAOYSA-N 0.000 description 1
- QGLKJKCYBOYXKC-UHFFFAOYSA-N nonaoxidotritungsten Chemical compound O=[W]1(=O)O[W](=O)(=O)O[W](=O)(=O)O1 QGLKJKCYBOYXKC-UHFFFAOYSA-N 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 238000003921 particle size analysis Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002964 rayon Substances 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000012209 synthetic fiber Substances 0.000 description 1
- 239000011135 tin Substances 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 229910001930 tungsten oxide Inorganic materials 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 229910001845 yogo sapphire Inorganic materials 0.000 description 1
- NAWDYIZEMPQZHO-UHFFFAOYSA-N ytterbium Chemical compound [Yb] NAWDYIZEMPQZHO-UHFFFAOYSA-N 0.000 description 1
- 229910052726 zirconium Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B22—CASTING; POWDER METALLURGY
- B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
- B22F1/00—Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B22—CASTING; POWDER METALLURGY
- B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
- B22F1/00—Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
- B22F1/14—Treatment of metallic powder
- B22F1/145—Chemical treatment, e.g. passivation or decarburisation
- B22F1/147—Making a dispersion
Definitions
- the present invention relates to antiviral compositions comprising particles of tungsten and/or tungsten compounds, and products, methods and uses relating thereto.
- the invention particularly relates to compositions comprising tungsten and its compounds for reducing and/or preventing the transmission of viruses.
- Salts containing tungsten are known to have antiviral activity.
- US 6,565,890 to Shigeta and Yamase discloses the use of heteropolyanions consisting of tungstoantimonate (III) vanadium-mixed metal oxide salts as antiviral drugs.
- Jelikic-Stankov et al (“Compounds of Mo, V and W in biochemistry and their biomedical activity", Journal of Trace Elements in Medicine and Biology, Volume 21, Issue 1, March 2007, Pages 8-16) report the use of polytungstosilicates for the in vitro inhibition of the leukaemia sarcoma virus.
- an antiviral composition comprising particles of a tungsten compound of general formula W n X y , wherein X is a non-metal, a metalloid or an anion and wherein n is equal to 1 or 2 and wherein y is equal to O, 1, 2 or 3.
- X is a non-metal, it is preferably selected from the group consisting of oxygen, nitrogen and carbon. More preferably, X is a non-metal and the tungsten compound is selected from the group consisting of WO, WO 2 , WO 3 , WC and W 2 C. Even more preferably, the tungsten compound is tungsten carbide. If X is an anion, it is preferably selected so as to provide an insoluble or sparingly soluble salt in water and common organic solvents. Suitably, X is an anion selected from the group consisting of phosphate, carbonate and silicate.
- X is a metalloid, it is preferably selected from the group consisting of silicon and tellurium.
- the particles comprise a compound as defined above where y has the value 1, 2 or 3 and n varies according to the oxidation state of tungsten in the compound.
- a composition comprising particles of tungsten metal and/or tungsten compounds have effective antiviral properties. Because the particles are insoluble or only sparingly soluble in solvents such as water, lower alcohols and acetone, they can be impregnated into materials such as polymers, used in applications such as surface coatings and liquid soaps, or otherwise used to provide a long-lasting or permanent antiviral substrate or article. The resulting article, coating, soap, suspension etc is able to destroy viruses on contact, thereby preventing and/or reducing transmission of the virus. Thus, the virus is destroyed prior to infection or, alternatively, the spread of infection is ameliorated.
- compositions according to the invention have a lower toxicity compared with other possible antiviral agents.
- particle is meant a solid particle which is not soluble, or only sparingly soluble, in solvents with which the particle might come into contact.
- the solvent is water or organic solvents which are commonly used for cleaning, washing etc (such as, for example, lower alcohols and acetone).
- the use of particles rather than soluble materials offers several advantages, including the ability to produce long-lasting or permanent coatings and better stability towards organics leaching from polymeric substrates.
- Particles for use in compositions according to the present invention may be any size, but preferably comprise micron and/or submicron particles, and more preferably substantially comprise submicron particles.
- submicron is generally meant particles having dimensions greater than nanometric dimensions, but less than about 1 ⁇ m, although submicron particles may have dimensions up to about 5 ⁇ m.
- Submicron particles are preferred over micron size particles because they provide high efficacy and good specific surface area, and are also readily available and easy to handle and disperse.
- the particles have an average particle size up to about 1 ⁇ m, more preferably up to about 2 ⁇ m, even more preferably up to about 3 ⁇ m and most preferably up to about 5 ⁇ m.
- the average particle size suitably lies in the range 0.5 ⁇ m to about 5 ⁇ m, more suitably from about 0.6 ⁇ m to about 4 ⁇ m and even more suitably from about 0.7 ⁇ m to about 3 ⁇ m.
- the particle size distribution by volume substantially comprises particles of size greater than 0.5 ⁇ m.
- the particles may be of a similar size to, smaller than or larger than any given target virus or viruses.
- the particles are in the form of powders, which may be applied to a surface or an article.
- the particles may also be dispersed in a liquid suspension or incorporated into a matrix such as, for example, sol-gels, coatings, or polymers, either in the form of solid components, fibres or foams.
- the particles may be agglomerated or in free association.
- the composition comprises tungsten metal particles doped, using known methods, with one or more elements selected from the group consisting of silicon, boron, phosphorous, arsenic, sulphur and gallium, and/or alloyed with one or more elements selected from the group consisting of aluminium, carbon, manganese, magnesium, nickel, tin, copper, titanium, tungsten, silver, iron and zinc.
- mixed particles may be composed of different elements as follows:
- the composition is a mixed composition comprising particles of W n X y , where the definition W n Xy includes doped and/or alloyed tungsten metal as described above, and one or more further particles.
- the one or more further particles may be selected from at least one oxide, preferably an oxide having antimicrobial and/or antifungal properties.
- the oxide is at least one of the following oxides : TiO 2 , Cu 2 O, CuO, ZnO, NiO, Al 2 O 3 , FeO 5 Fe 2 O 3 , Fe 3 O 4 , CoO, Co 3 O 4 , ZrO 2 or Si 2 O 3 , or a combination thereof.
- a mixed composition comprising tungsten carbide and TiO 2 particles is particularly preferred.
- the one or more further particles may be an environmental catalyst such as, for example, ZnO or TiO 2 .
- a mixed composition may alternatively comprise one or more compounds of general formula W n X y as described above, together with additional elements selected from the group consisting of: boron, carbon, aluminium, silicon, phosphorous, calcium, titanium, chromium, manganese, iron, cobalt, silver, zinc, copper, sulfur, nickel, gold, zirconium, ytterbium, or a combination thereof.
- Mixed particle compositions may be produced by any suitable method, such as, for example, tumble-mixing, co-deposition or mechanical alloying, or by co-production. This may result in a composition substantially comprising submicron particles, both micron/micron sized particles or combinations of micron and submicron particles, with or without additional agglomeration.
- the W n Xy particles may be prepared as layered (core/shell) particles comprising an outer shell of tungsten metal or a tungsten compound in accordance with the invention and an inner shell of another material.
- particles having a core of tungsten metal with an outer shell of a tungsten compound, preferably tungsten carbide or tungsten oxide, can be used.
- Particles of tungsten metal and tungsten compounds can be synthesized by any suitable method and such methods are well known to those skilled in the art.
- suitable methods are thermal processes such as gas phase reduction of large particles, grinding and milling (where the ultimate size depends upon the size, morphology and composition of the grinding medium, process variables, design and operation of the mill etc) and inflight chemical processes using reaction vessels. All of these processes can be tuned to deliver a variation of particle size, in some cases resulting in pure materials, in others requiring additional post processing to deliver the required materials.
- the reduction and/or prevention of virus transmission may be defined as a reduction on viral titre of at least 90% following administration of a composition of particles as defined herein to a preparation of virus.
- the reduction on viral titre is at least 93%, 94% or 95%, most preferably 98%, 99% or 100%. Reduction and/or prevention of virus transmission is demonstrated by the inactivation of virus upon contact with the particles.
- a reduction in viral titre of 70% or less is not an effective reduction sufficient to avoid infection.
- the present invention provides a means for reducing viral titre such that infection is prevented or avoided to a significant extent.
- Viral titre is a quantification of the number of virus particles in a given sample. It may be performed by using the haemagglutination assay (HA). Viral families have surface or envelope proteins that are able to agglutinate animal red blood cells (RBCs) and bind to N-acetylneuraminic acid residues on the cell surface of the RBCs. The RBC forms a type of lattice following viral binding which can be quantified.
- the HA procedure is an easy, simple and rapid method which is well known to those skilled in the art.
- the detailed assay conditions depend on the type of virus, some viruses binding RBCs only at certain pH values and others at certain ionic strengths. However, these are well known to the skilled person and can be readily identified according to the virus in question. A virus dilution is applied to an RBC dilution for a suitable period of time under appropriate conditions. Subsequently, the formation of lattices will be counted and the titre calculated.
- the end point of the haemagglutination assay is defined as the lowest contraction of the virus (highest diluents) that still caused haemagglutination.
- the titre of the virus is recorded as haemagglutination units (HAV) and is directly related to the dilution in the end point of well.
- the present invention provides a means to reduce the viral titre of a virus.
- the virus is selected from the group consisting of Influenza, Measles, Coronavirus, Mumps,
- SARS virus Severe Acute Respiratory Syndrome virus or SARS virus (also referred to as SARS coronavirus), Human Immunodeficiency Virus (HFV), and associated non-human animal immunodeficiency retroviruses such as Simian Immunodeficiency Virus (SIV), Rotavirus, Norwalk virus and Adenovirus.
- SARS coronavirus also referred to as SARS coronavirus
- HBV Human Immunodeficiency Virus
- SIV Simian Immunodeficiency Virus
- Rotavirus Norwalk virus
- Norwalk virus includes its surrogate Feline
- Influenza viruses include both human and avian forms of the virus. Foot- and-Mouth virus is also a preferred target virus.
- the antiviral composition may be formulated in an appropriate carrier, coating or solvent such as water, methanol, ethanol, acetone, water soluble polymer adhesives, such as polyvinyl acetate (PVA), epoxy resin, polyesters etc, as well as coupling agents and antistatic agents. Solutions of biological materials may also be used such as phosphate buffered saline (PBS) or simulated biological fluid (SBF).
- PBS phosphate buffered saline
- SBF simulated biological fluid
- concentration of particles in the solution may lie in the range of from 0.001% (wt) to about 20% (wt).
- a composition according to the invention can be used in powder form, either coated onto or impregnated into a surface or article, or mixed with an absorbent powder such as Fullers earth or sand.
- Reduction and/or prevention of virus transmission includes the prevention of viral infection of a subject with a virus, in addition to the prevention of viral transmission from a first location to a second location, for example from an external space to an internal lumen, or the prevention of viral transmission through a barrier material.
- the subject may be a human or a non-human animal, suitably a non-human mammal.
- the present invention may therefore find application in the fields of human medicine and animal veterinary medicine as well as in the field of infection control in a non-medical context, such as a prophylactic against viral transmission or against such diseases as Foot-and- Mouth.
- compositions according to the present invention can be applied to enclosed ventilation fabrics for public buildings, hospitals, and modes of transport such as vehicles, cars, trains, ships and aeroplanes.
- the compositions may also find use in medical applications, such as in filtering materials, i.e. in filtration of biological fluids such as plasma, blood, milk, semen etc to inactivate virus.
- the antiviral particles may be coated onto fabrics and surfaces of different products such as furniture, paints/coatings, book covers, computer keyboard in order to produce products and surfaces with antiviral properties.
- Such products will provide a low cost virus-free environment for hospitals, children, patients and the elderly.
- Further uses may include air ventilation systems for enclosed environments such as passenger aeroplanes, large buses and cars, for preventing the entry or outlet of particles of airborne influenza viruses and other infectious viruses.
- a second aspect of the invention provides an article and/or antiviral surface coated or impregnated with an antiviral composition as described above.
- at least one active surface of the article and/or surface i.e. a surface which comes into contact with virus-bearing objects or media, is coated or impregnated with the composition.
- protective clothing may comprise fabrics and/or fibres coated with the antiviral composition and the exposed surface of filters may be coated with the composition.
- the coating and/or impregnation process may be any suitable method, such as, for example, spray coating, electro-spray coating, dipping or plasma coating.
- the article may be selected from the group consisting of filters, face masks, surgical masks, respirator masks, hats, hoods, trousers, shirts, gloves, skirts, boiler-suits, surgical gowns, medical and vetinary devices and prophylactic devices.
- surfaces that are routinely contacted by people, especially in communal areas, such as, for example, toilets, doors, handles, buttons, switches, keyboards etc, may be coated and/or impregnated with the composition.
- areas of food preparation and utensils or equipment used therein may be coated with a compound according to the invention, such as, for example, chopping boards, knives, bowls, surfaces etc.
- Filters may be prepared from any suitable natural or artificial material.
- the filter may be an air filter.
- An air filter is a device which removes contaminants, often solid particles from air. Air filters are often used in diving air compressors, ventilation systems and any other situation in which air quality is important, such as in air-conditioning units.
- An air filter includes devices which filter air in an enclosed space such as a building or a room, as well as apparatus or chambers for handling viral materials. Other articles which perform a protective function such as curtains or screens may therefore also be considered as air filters.
- Air filters may be composed of paper, foam, cotton filters, or spun fibreglass filter elements. Alternatively, the air filter may use fibers or elements with a static electric charge. There are four main types of mechanical air filters: paper, foam, synthetics and cotton.
- Polyester fiber can be used to make web formations used for air filtration. Polyester can be blended with cotton or other fibers to produce a wide range of performance characteristics. In some cases polypropylene may be used. Tiny synthetic fibers knows as micro-fibers may be used in many types of high efficiency particulate air (HEPA) filters. High performance air filters may use oiled layers of cotton gauze.
- HEPA high efficiency particulate air
- the filter may be used to filter liquids.
- Such filters may be composed of any suitable fibre as described above. Filters used to filter liquids may be used to filter potable liquids for human or animal consumption, water for general domestic use, fluids for medical use, such as plasma or saline solutions, or pharmaceutical formulations for injection, or other biological liquids which may come into contact with a patient.
- Articles of protective clothing are suitably composed of fibres which are coated with a composition of particles as defined above.
- the article of protective clothing may be a face mask. Such masks may cover the whole face of the user or a part thereof, suitably the external areas of the nose and/or mouth of the wearer.
- the article of protective clothing may be prepared from any suitable fibre or fabric and may comprise natural and/or artificial fibres.
- Suitable natural fibres include cotton, wool, cellulose (including paper materials), silk, hair, jute, hemp, sisal, flex, wood, bamboo, metal or carbon.
- Suitable artificial fibres include polyester, rayon, nylon, Kevlar ® , lyocell (Tencell ® ), polyethylene, polypropylene, polyimide, polymethyl methacrylate, poly (carboxylato phenoxy) phosphazene (PCPP), fibre glass (glass) or ceramics.
- the article of clothing may be selected from the group consisting of face masks (surgical masks, respirator masks), hats, hoods, trousers, shirts, gloves, skirts, boiler suits and surgical gowns (scrubs). Such clothing may find particular use in a hospital where control of infection is of paramount importance.
- the articles of clothing or filters may be made of mixed fibres from any source as described above.
- a face mask or a filter may be composed of a fibrous material which has been coated with a particle composition as defined herein.
- compositions, surface or article as described above for reducing and/or preventing virus transmission.
- the tungsten compound is tungsten carbide, more preferably the tungsten carbide takes the form of substantially submicron particles and even more preferably the tungsten carbide takes the form of particles having an average size in the range 0.7 ⁇ m to 3 ⁇ m and/or a particle size distribution by volume substantially comprising particles of size greater than 0.5 ⁇ m.
- a method for the reduction and/or prevention of virus transmission comprising the step of applying to an article or surface a composition comprising particles of a tungsten compound of general formula W n Xy, wherein X is a non-metal, a metalloid or an anion and wherein n is equal to 1 or 2 and wherein y is equal to 0, 1, 2 or 3.
- X is a non-metal, it is preferably selected from the group consisting of oxygen, nitrogen and carbon. More preferably, X is a non-metal and the tungsten compound is selected from the group consisting of WO, WO 2 , WO 3 , WC and W 2 C. Even more preferably, the tungsten compound is tungsten carbide.
- X is an anion, it is preferably selected so as to provide an insoluble or sparingly soluble salt in water and common organic solvents.
- X is an anion selected from the group consisting of phosphate, carbonate and silicate.
- X is a metalloid, it is preferably selected from the group consisting of silicon or tellurium.
- the present invention also provides the use of mixed particles compositions for reducing and/or preventing virus transmission. Such mixed particles of the invention may also be used in methods, articles and surfaces described above.
- a sample of 99.5% tungsten carbide supplied by Alfa Aesar having a nominal particle size of less than 1 ⁇ m was tested for antiviral activity against the H5N1 Influenza NIBRG- 14 virus, using the HA procedure and Madin-Darby Canine Kidney (MDCK) cells.
- Particle size analysis showed that substantially all of the volume fraction of the sample comprised particles having a size greater than 0.5 ⁇ m and that the average particle size by volume was between 0.7 ⁇ m and 3 ⁇ m.
- the amount of virus tested against in the "reaction mixture” was 10 6 5 TCID 50 ZmI (Tissue Culture Infective Units).
- the virus was diluted in distilled water and then added to the tungsten carbide particles to form the "reaction mixture”.
- the reaction mixture was lightly vortexed (mixed) at room temperature and then incubated for a further 30 minutes at room temperature while being shaken on a plate shaker to ensure continual contact of the tungsten carbide particles with the virus particles.
- the reaction mixtures were centrifuged to separate the tungsten carbide particles from the virus and then added to cell maintenance media in preparation for infecting the MDCK cells.
- the virus was then quantified by making serial dilutions of the reaction mixture on MDCK cells to generate the "infective" titre (Log ⁇ o TCID 50 ZmI).
- a "negative control” no tungsten carbide mixed with the virus
- a "positive control” of citric acid a solution with a pH of approximately 3.5
- the effect of the tungsten carbide particles on the virus is shown in Table 1 as reduction in virus titre (% and LOg 10 TCIDso/ml), together with the results for the positive and negative controls. Comparing the amount of virus in the negative control (virus but no tungsten carbide sample) with the reaction mixture containing the tungsten carbide sample gives the reduction in amount of infective virus (shown as Log 10 TCID 5 o/ml or %), which reduction is close to the detectable limits of the assay. The positive control (low pH) reduced the infectivity of the virus to below detectable limits of the assay such that no virus was observed to remain.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Inorganic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pest Control & Pesticides (AREA)
- Agronomy & Crop Science (AREA)
- Plant Pathology (AREA)
- Engineering & Computer Science (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Virology (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La présente invention concerne une composition antivirale contenant des particules d'un composé de tungstène représenté par la formule générale WnXy5 dans laquelle X est un non-métal, un métalloïde ou un anion, dans laquelle n est égal à 1 ou 2 et dans laquelle y est égal à 0, 1, 2 ou 3. Si X est un non-métal, il est de préférence choisi parmi le groupe constitué d'oxygène, d'azote et de carbone. Mieux encore, X est un non-métal et le composé de tungstène est choisi parmi le groupe constitué de WO, WO2, WO3, WC et W2C et, idéalement, le composé de tungstène est du carbure de tungstène. Si X est un anion, il est de préférence choisi de manière à fournir un sel insoluble ou peu soluble dans l'eau et les solvants organiques communs. X peut également être un anion choisi parmi le groupe constitué de phosphate, de carbonate et de silicate, ou un métalloïde choisi parmi le groupe constitué de silicium ou de tellure. De préférence, les particules sont de taille submicronique. L'invention propose également un article et des surfaces revêtus ou imprégnés de composition antivirales, et des procédés et des utilisations s'y rapportant.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0715728.2 | 2007-08-11 | ||
GB0715728A GB2451824A (en) | 2007-08-11 | 2007-08-11 | Antiviral composition comprising particles of a tungsten compound |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009022100A1 true WO2009022100A1 (fr) | 2009-02-19 |
Family
ID=38543463
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2008/002660 WO2009022100A1 (fr) | 2007-08-11 | 2008-08-05 | Composition contenant des particules de composé métallique |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB2451824A (fr) |
WO (1) | WO2009022100A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011018899A1 (fr) * | 2009-08-12 | 2011-02-17 | 株式会社 東芝 | Matériel antiviral et film, fibre, et produit l'utilisant |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2004846A (en) * | 1977-09-28 | 1979-04-11 | Westinghouse Brake & Signal | >Improvements in or relating to rotary airlocks |
WO1992012827A1 (fr) * | 1991-01-25 | 1992-08-06 | Carbide Tools International A/S | Bande de sablage |
WO1996023907A1 (fr) * | 1995-02-01 | 1996-08-08 | Kennametal Inc. | Matrice pour materiau composite dur |
US6066407A (en) * | 1998-06-15 | 2000-05-23 | Getz; Roland A. | Wear resistant parts for hammers and chippers |
US20040096469A1 (en) * | 2002-11-14 | 2004-05-20 | Lewis Jennifer A. | Controlled dispersion of colloidal suspensions by comb polymers |
US20050196355A1 (en) * | 2004-03-03 | 2005-09-08 | Constantine Georgiades | Film products having controlled disintegration properties |
WO2006123937A2 (fr) * | 2005-05-20 | 2006-11-23 | Ge Healthcare As | Agents de contraste |
WO2006123936A2 (fr) * | 2005-05-20 | 2006-11-23 | Ge Healthcare As | Agents de contraste |
WO2007093808A2 (fr) * | 2006-02-16 | 2007-08-23 | Queen Mary & Westfield College | Substances virucides |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1078188C (zh) * | 1997-01-02 | 2002-01-23 | 中国人民解放军济南军区联勤部军事医学研究所 | 自消毒搪、陶瓷材料及其制备方法 |
JP2000041667A (ja) * | 1998-08-04 | 2000-02-15 | Terumo Corp | 光触媒を用いたウイルス不活化システム |
US7473675B2 (en) * | 2005-02-25 | 2009-01-06 | Solutions Biomed, Llc | Disinfectant systems and methods comprising a peracid, alcohol, and transition metal |
US20060210798A1 (en) * | 2005-03-16 | 2006-09-21 | Clemens Burda | Doped metal oxide nanoparticles and methods for making and using same |
AT12981U1 (de) * | 2006-11-13 | 2013-03-15 | Josef Peter Dr Guggenbichler | Stoff mit antimikrobieller wirkung |
-
2007
- 2007-08-11 GB GB0715728A patent/GB2451824A/en not_active Withdrawn
-
2008
- 2008-08-05 WO PCT/GB2008/002660 patent/WO2009022100A1/fr active Application Filing
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2004846A (en) * | 1977-09-28 | 1979-04-11 | Westinghouse Brake & Signal | >Improvements in or relating to rotary airlocks |
WO1992012827A1 (fr) * | 1991-01-25 | 1992-08-06 | Carbide Tools International A/S | Bande de sablage |
WO1996023907A1 (fr) * | 1995-02-01 | 1996-08-08 | Kennametal Inc. | Matrice pour materiau composite dur |
US6066407A (en) * | 1998-06-15 | 2000-05-23 | Getz; Roland A. | Wear resistant parts for hammers and chippers |
US20040096469A1 (en) * | 2002-11-14 | 2004-05-20 | Lewis Jennifer A. | Controlled dispersion of colloidal suspensions by comb polymers |
US20050196355A1 (en) * | 2004-03-03 | 2005-09-08 | Constantine Georgiades | Film products having controlled disintegration properties |
WO2006123937A2 (fr) * | 2005-05-20 | 2006-11-23 | Ge Healthcare As | Agents de contraste |
WO2006123936A2 (fr) * | 2005-05-20 | 2006-11-23 | Ge Healthcare As | Agents de contraste |
WO2007093808A2 (fr) * | 2006-02-16 | 2007-08-23 | Queen Mary & Westfield College | Substances virucides |
Non-Patent Citations (1)
Title |
---|
IVANKOVIC S ET AL: "PHOTOKILLING SQUAMOUS CARCINOMA CELLS SCCVII WITH ULTRAFINE PARTICLES OF SELECTED METAL OXIDES", JOURNAL OF SOL-GEL SCIENCE AND TECHNOLOGY, SPRINGER, NEW YORK, NY, US, vol. 27, no. 2, 1 June 2003 (2003-06-01), pages 225 - 233, XP001167798, ISSN: 0928-0707 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011018899A1 (fr) * | 2009-08-12 | 2011-02-17 | 株式会社 東芝 | Matériel antiviral et film, fibre, et produit l'utilisant |
JPWO2011018899A1 (ja) * | 2009-08-12 | 2013-01-17 | 株式会社東芝 | 抗ウイルス性材料とそれを用いた膜、繊維および製品 |
US8741349B2 (en) | 2009-08-12 | 2014-06-03 | Kabushiki Kaisha Toshiba | Antiviral material , antiviral film, antiviral fiber, and antiviral product |
JP5780960B2 (ja) * | 2009-08-12 | 2015-09-16 | 株式会社東芝 | 抗ウイルス性材料とそれを用いた膜および製品 |
JP2015193973A (ja) * | 2009-08-12 | 2015-11-05 | 株式会社東芝 | 抗ウイルス性繊維 |
US10327445B2 (en) | 2009-08-12 | 2019-06-25 | Kabushiki Kaisha Toshiba | Antiviral material, antiviral film, antiviral fiber, and antiviral product |
Also Published As
Publication number | Publication date |
---|---|
GB0715728D0 (en) | 2007-09-19 |
GB2451824A (en) | 2009-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chua et al. | Face masks in the new COVID-19 normal: materials, testing, and perspectives | |
Karim et al. | Sustainable personal protective clothing for healthcare applications: a review | |
Babaahmadi et al. | Biodegradable and multifunctional surgical face masks: A brief review on demands during COVID-19 pandemic, recent developments, and future perspectives | |
Seidi et al. | Functionalized masks: powerful materials against COVID‐19 and future pandemics | |
US20100040655A1 (en) | Anti-viral Formulations Nanomaterials And Nanoparticles | |
CN106102863B (zh) | 带有由不同电纺纤维相互交织而成的涂层的防护口罩、构成所述涂层的配方、以及制作所述防护口罩的方法 | |
Sadique et al. | High-performance antiviral nano-systems as a shield to inhibit viral infections: SARS-CoV-2 as a model case study | |
TWI378773B (en) | Antimicrobial compositions and fibres incorporating the same | |
JP2008508060A (ja) | 抗微生物性エアフィルター | |
WO2010136792A2 (fr) | Composition antibactérienne | |
KR102498787B1 (ko) | 생분해능과 항균능을 갖는 부직포 원단, 이의 제조방법 및 이를 포함하는 개인용품 | |
US20110114095A1 (en) | Antiviral metal impregnated activated carbon cloth components | |
Feng et al. | Ag/Zn galvanic couple cotton nonwovens with breath-activated electroactivity: a possible antibacterial layer for personal protective face masks | |
WO2022255885A1 (fr) | Filtres contenant des nanofibres chargées de terpène pour une activité bactéricide, fongicide et virucide améliorée, leurs procédés de préparation et leurs applications | |
El-Atab et al. | Toward nanotechnology-enabled face masks against SARS-CoV-2 and pandemic respiratory diseases | |
Chiome et al. | Use of antiviral nanocoating in personal protective wear | |
Neupane et al. | Current understanding on the effectiveness of face masks and respirators to prevent the spread of respiratory viruses | |
WO2010015801A2 (fr) | Composition biocide | |
WO2021229444A1 (fr) | Nouveau masque facial biodégradable amélioré ayant des propriétés intrinsèques virucides, hydrophobes et hydrophiles comportant des boucles latérales réglables | |
CN100382705C (zh) | 纳米抗菌材料及其制备方法 | |
JP2023545243A (ja) | グラフェン-銀ナノコンポジット及び抗微生物組成物としてのその使用 | |
Zhang et al. | The rise of electroactive materials in face masks for preventing virus infections | |
Sheraz et al. | SARS-CoV-2 airborne transmission: a review of risk factors and possible preventative measures using air purifiers | |
WO2009022100A1 (fr) | Composition contenant des particules de composé métallique | |
Wang et al. | Reusable electrospun nanofibrous membranes with antibacterial activity for air filtration |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08776135 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08776135 Country of ref document: EP Kind code of ref document: A1 |